Nanexa
3.71 SEK
-1.46 %
Less than 1K followers
NANEXA
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Nanexa
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 1.7 | 2.4 | 2.4 | 2.9 | 29.3 | 24.4 | 36.1 |
| growth-% | 38.4 % | 0.3 % | 20.5 % | 925.5 % | -16.9 % | 48.4 % | |
| EBITDA | -9.3 | -16.3 | -28.4 | -47.5 | -16.8 | -15.2 | - |
| EBIT | -12.7 | -21.5 | -35.8 | -58.0 | -76.6 | -26.1 | -8.8 |
| Profit before taxes | -13.0 | -21.7 | -36.0 | -58.6 | -76.3 | -24.8 | -11.5 |
| Net income | -13.0 | -21.7 | -36.0 | -58.6 | -76.4 | -24.9 | -11.4 |
| EPS | -0.78 | -1.01 | -1.01 | -1.16 | -1.09 | -0.18 | -0.07 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -541.4 % | -688.0 % | -1,194.3 % | -1,660.1 % | -57.1 % | -62.4 % | |
| EBIT-% | -743.3 % | -907.9 % | -1,508.9 % | -2,027.3 % | -261.3 % | -107.0 % | -24.3 % |
| ROE | -52.1 % | -50.1 % | -23.8 % | -53.7 % | -79.7 % | -35.1 % | -11.2 % |
| ROI | -36.5 % | -40.5 % | -21.8 % | -34.4 % | -57.5 % | -27.1 % | -8.2 % |